Asset profile
VH3739937
Small molecule
Evidence outlook · lead readout
NCT04493684 · HIV Infections
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT04493684: A randomized, double-blind, placebo-controlled first-in-human study of VH3739937 in 91 healthy participants. Randomization and blinding are real, but the primary measures are descriptive safety, laboratory, and pharmacokinetic parameters with no formal efficacy comparison, so this is moderate evidence of tolerability rather than efficacy.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.